Literature DB >> 2499546

Relationship between levels of Clostridium difficile toxin A and toxin B and cecal lesions in gnotobiotic mice.

A Vernet1, G Corthier, F Dubos-Ramaré, A L Parodi.   

Abstract

Various Clostridium difficile strains were studied with respect to their pathogenicity in monoassociated mice in relation to levels of toxin A and toxin B in vivo and in vitro. Two strains which were the most potent toxin producers in vitro induced mortality (100%); mice monoassociated with these strains were found to have high levels of both toxins in their ceca and an intense cecal epithelial ulceration together with a severe inflammatory process. No mortality was observed with the other strains. Strains which were moderately toxinogenic in vitro induced inflammation of the cecum but no ulceration, and no toxin A was found. Inflammation intensity was not related to toxin B levels. After 3 weeks, ceca returned to normal in spite of a chronic cytotoxin production. When compared with in vitro results, which showed a good correlation between the levels of the two toxins, toxin A amounts in vivo were found to be lowered relative to toxin B levels. The lack of detectable toxin A levels in animals infected with all but the two most highly toxinogenic strains prevented death. This work points out the importance of investigation of toxin A for the understanding of C. difficile pathogenicity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2499546      PMCID: PMC313850          DOI: 10.1128/iai.57.7.2123-2127.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

1.  [Microflora of the digestive system of the rat. I. Technics of study and proposed culture media].

Authors:  P Raibaud; A B Dickinson; E Sacquet; H Charlier; G Mocquot
Journal:  Ann Inst Pasteur (Paris)       Date:  1966-04

2.  Identification of Clostridium difficile as a cause of pseudomembranous colitis.

Authors:  R H George; J M Symonds; F Dimock; J D Brown; Y Arabi; N Shinagawa; M R Keighley; J Alexander-Williams; D W Burdon
Journal:  Br Med J       Date:  1978-03-18

3.  Emergence in gnotobiotic mice of nontoxinogenic clones of Clostridium difficile from a toxinogenic one.

Authors:  G Corthier; M C Muller
Journal:  Infect Immun       Date:  1988-06       Impact factor: 3.441

4.  Clostridium difficile toxin A in infants.

Authors:  J M Libby; S T Donta; T D Wilkins
Journal:  J Infect Dis       Date:  1983-09       Impact factor: 5.226

5.  Isolation of Clostridium difficile from the feces and the antibody in sera of young and elderly adults.

Authors:  S Nakamura; M Mikawa; S Nakashio; M Takabatake; I Okado; K Yamakawa; T Serikawa; S Okumura; S Nishida
Journal:  Microbiol Immunol       Date:  1981       Impact factor: 1.955

6.  Comparison of two toxins produced by Clostridium difficile.

Authors:  N S Taylor; G M Thorne; J G Bartlett
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

7.  Pseudomembranous colitis in Clostridium difficile-monoassociated rats.

Authors:  C J Czuprynski; W J Johnson; E Balish; T Wilkins
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

8.  Enzyme-linked immunosorbent assay for Clostridium difficile toxin A.

Authors:  D M Lyerly; N M Sullivan; T D Wilkins
Journal:  J Clin Microbiol       Date:  1983-01       Impact factor: 5.948

9.  Clostridium difficile in gnotobiotic mice.

Authors:  A B Onderdonk; R L Cisneros; J G Bartlett
Journal:  Infect Immun       Date:  1980-04       Impact factor: 3.441

10.  Clostridium difficile and the aetiology of pseudomembranous colitis.

Authors:  H E Larson; A B Price; P Honour; S P Borriello
Journal:  Lancet       Date:  1978-05-20       Impact factor: 79.321

View more
  7 in total

Review 1.  Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review.

Authors:  Marwan S Abougergi; John H Kwon
Journal:  Dig Dis Sci       Date:  2010-10-06       Impact factor: 3.199

2.  Murine model of Clostridium difficile infection with aged gnotobiotic C57BL/6 mice and a BI/NAP1 strain.

Authors:  S W Pawlowski; G Calabrese; G L Kolling; J Platts-Mills; R Freire; C AlcantaraWarren; B Liu; R B Sartor; R L Guerrant
Journal:  J Infect Dis       Date:  2010-10-26       Impact factor: 5.226

3.  Antibiotic treatment of clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts.

Authors:  Trevor D Lawley; Simon Clare; Alan W Walker; David Goulding; Richard A Stabler; Nicholas Croucher; Piero Mastroeni; Paul Scott; Claire Raisen; Lynda Mottram; Neil F Fairweather; Brendan W Wren; Julian Parkhill; Gordon Dougan
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

4.  A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.

Authors:  Nicola L Davies; Joanne E Compson; Brendon Mackenzie; Victoria L O'Dowd; Amanda K F Oxbrow; James T Heads; Alison Turner; Kaushik Sarkar; Sarah L Dugdale; Mark Jairaj; Louis Christodoulou; David E O Knight; Amanda S Cross; Karine J M Hervé; Kerry L Tyson; Hanna Hailu; Carl B Doyle; Mark Ellis; Marco Kriek; Matthew Cox; Matthew J T Page; Adrian R Moore; Daniel J Lightwood; David P Humphreys
Journal:  Clin Vaccine Immunol       Date:  2013-01-16

5.  Heterogeneity of Clostridium difficile isolates from infants.

Authors:  A Collignon; L Ticchi; C Depitre; J Gaudelus; M Delmée; G Corthier
Journal:  Eur J Pediatr       Date:  1993-04       Impact factor: 3.183

Review 6.  Clostridium difficile: clinical disease and diagnosis.

Authors:  F C Knoop; M Owens; I C Crocker
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

7.  Interrelationships between digestive proteolytic activities and production and quantitation of toxins in pseudomembranous colitis induced by Clostridium difficile in gnotobiotic mice.

Authors:  G Corthier; M C Muller; G W Elmer; F Lucas; F Dubos-Ramaré
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.